

invitation

Moss Capital is pleased to invite you to a rare opportunity for a Q&A session with a pre-eminent leader in molecular biology, Sir Gregory Winter in Sydney on 24 January 2012. Also presenting will be key Executives from Biosceptre International Limited.



Sir Gregory has received numerous international prizes and awards and in 2004 was knighted for services to Molecular Biology. He was a Founder and Director of Cambridge Antibody Technology (acquired by Astra Zeneca), a Founder and Director of Domantis (acquired by GSK) and more recently a Founder and Director of Bicycle Therapeutics.

Sir Gregory Winter is a member of the UK Medical Research Council's Laboratory of Molecular Biology in Cambridge and was recently appointed Master of Trinity College Cambridge.

Based in Cambridge for most of his scientific career, his work included protein sequencing and nucleic acid sequencing. He later developed technologies for making humanised antibodies and also for making human antibodies in bacteria. Most of the therapeutic antibodies on the market were developed using methods devised by Sir Gregory.

Biosceptre International Ltd is a company which has discoveries pertaining to a broad range of cancer types and is now undergoing rapid change from discovery to product development. The value of Biosceptre's discoveries are corroborated by the recent endorsement of a world leading Scientific Advisory Board, chaired by Sir Gregory Winter. In August 2011 the company secured \$AUD8m in funding and is on track for FDA IND (US Food and Drug Administration Investigational New Drug) submission in 2012 and commencement of clinical trials for one of its products. The company is presently seeking a further \$15AUD million in capital to progress another lead therapeutic program to clinical trials in humans.

We expect demand for places at this rare opportunity to be high from the scientific and investment community.

Date: Tuesday, 24 January 2012
Time: 1:00pm to 3:00pm
Followed by open discussion and light refreshments
Venue: Sofitel Sydney Wentworth
The Boardroom
61-101 Phillip Street
Sydney NSW 2000

Places are strictly limited.

To secure your place, register now by contacting:

Email: colin.prasad@mosscapital.com.au
Phone: Skye Evans at Moss Capital
on 02 9239 8406

MOSSCAPITAL



Biosceptre
International Limited